Alnylam (ALNY) Continues to Expand RNAi Capabilities; FBR Affirms at 'Outperform'
Tweet Send to a Friend
FBR affirmed its Outperform rating and $180 price target on Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) after the company announced advancement ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
